0001144204-19-033657.txt : 20190702
0001144204-19-033657.hdr.sgml : 20190702
20190702185727
ACCESSION NUMBER: 0001144204-19-033657
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190628
FILED AS OF DATE: 20190702
DATE AS OF CHANGE: 20190702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36721
FILM NUMBER: 19939565
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Coherus BioSciences, Inc.
CENTRAL INDEX KEY: 0001512762
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273615821
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (650) 649-3530
MAIL ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: BioGenerics, Inc.
DATE OF NAME CHANGE: 20110210
4
1
tv524689_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-06-28
0
0001512762
Coherus BioSciences, Inc.
CHRS
0001245624
HEALY JAMES
C/O SOFINNOVA INVESTMENTS, INC., 3000
SAND HILL ROAD, BLDG. 4, SUITE 250
MENLO PARK
CA
94025
1
0
0
0
Common Stock, $0.0001 par value
2019-06-28
4
S
0
200000
22.05
D
2093221
I
See Footnote
Common Stock, $0.0001 par value
2019-07-02
4
S
0
160000
22.61
D
1933221
I
See Footnote
Common Stock, $0.0001 par value
92
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Venture Partners VII, L.P. on August 23, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.17, inclusive. The reporting person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.
/s/ Nathalie Auber, as Attorney in Fact for James I. Healy, M.D., Ph.D.
2019-07-02